Aclaris Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Aclaris Therapeutics

03/08/2026 14:45

Aclaris Therapeutics Inc ACRS.OQ ACRS.O is expected to  show a fall in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026
The Wayne Pennsylvania-based  company is expected to report a 22.2% decrease in revenue to $1.383 million from $1.78 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Aclaris Therapeutics Inc is for a loss of 16 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Aclaris Therapeutics Inc is $10.00, about 92.3% above its last closing price of $5.20
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.16
-0.16
-0.15
Beat
4.9
Dec. 31 2026
-0.14
-0.15
-0.16
Missed
-6.7
Sep. 30 2025
-0.13
-0.13
-0.12
Beat
11.1​
Jun. 30 2025
-0.14
-0.13
-0.13
Met
2.2
​​Mar. 31 2025
-0.12
-0.12
-0.12
Met
-2.1
Dec. 31 2024
-0.20
-0.22
-1.01
Missed
-362.1​
Sep. 30 2024
0.04
-0.01
-0.11
Missed
-1,826.4
Jun. 30 2024
-0.20
-0.20
-0.15
Beat
26.6
This summary was machine generated August 3 at 13:45 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)